FDA approves Opdivo for Metastatic Melanoma-BMS

The FDA has granted approval of Opdivo (nivolumab), from BMS, for indicated for the treatment of patients with unresectable or Metastatic Melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. The drug is approved under accelerated approval based on tumor response rate and durability of response.